Article Text

Download PDFPDF
Does Paclitaxel-Carboplatin Chemotherapy in a Dose-Dense Regimen Enhance Survival of BRCA-Related Ovarian Cancer Patients?
  1. Karin Leunen, MD*,
  2. Isabelle Cadron, MD*,
  3. Toon Van Gorp, MD*,
  4. Frédéric Amant, MD, PhD*,
  5. Patrick Berteloot, MD*,
  6. Patrick Neven, MD, PhD*,
  7. Eric Legius, MD, PhD and
  8. Ignace Vergote, MD, PhD*
  1. * Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and
  2. Department of Human Genetics, University Hospitals Leuven, Leuven, Belgium.
  1. Address correspondence and reprint requests to Karin Leunen, MD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. E-mail: karin.leunen{at}uz.kuleuven.ac.be.

Abstract

In a group of 6 BRCA-related ovarian cancer patients presenting with clinical relapse, paclitaxel-carboplatin (TC) in a dose-dense regimen was administered to evaluate the response and tolerability compared with those of the sporadic group and of the patients using a regimen administered every 3 weeks.

All patients were carboplatin sensitive at the time of first relapse: 4 patients showed intermediate sensitivity (6-12 months), and 2 patients were truly carboplatin sensitive (>12 months) at first relapse and first administration of a TC dose-dense regimen. A total of 14 dose-dense regimens were administered in a median 5th line (range, 2nd-10th line). A median of 2 dose-dense regimens (range, 1-4) was given per patient. After first administration of the TC dose-dense regimen (median, 3rd line), this resulted in response in all patients: complete remission in 33% and partial remission in the remaining 67%. Furthermore, after another consecutive line of TC dose-dense regimen, 100% response (75% with partial remission and 25% with complete remission) was reached.

The results are encouraging and support the observation of extreme carboplatin sensitivity of BRCA-related ovarian cancer. The use of a TC dose-dense regimen might be even more effective.

  • Ovarian cancer
  • BRCA
  • Dose-dense regimen

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflict of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.